Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) Non Operating Income (2019 - 2025)

Bioadaptives' Non Operating Income history spans 7 years, with the latest figure at -$113813.0 for Q3 2025.

  • For Q3 2025, Non Operating Income fell 235.02% year-over-year to -$113813.0; the TTM value through Sep 2025 reached $25055.0, up 105.34%, while the annual FY2024 figure was -$297071.0, 38.56% up from the prior year.
  • Non Operating Income for Q3 2025 was -$113813.0 at Bioadaptives, down from $121305.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $138337.0 in Q3 2021 and bottomed at -$278011.0 in Q1 2021.
  • The 5-year median for Non Operating Income is -$87968.0 (2023), against an average of -$84665.7.
  • The largest annual shift saw Non Operating Income skyrocketed 1135.48% in 2021 before it tumbled 21081.23% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$36549.0 in 2021, then skyrocketed by 97.33% to -$975.0 in 2022, then crashed by 21081.23% to -$206517.0 in 2023, then surged by 83.32% to -$34449.0 in 2024, then plummeted by 230.38% to -$113813.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Non Operating Income are -$113813.0 (Q3 2025), $121305.0 (Q2 2025), and $52012.0 (Q1 2025).